Trends in exposure to televised prescription drug advertising, 2003-2011

American Journal of Preventive Medicine

Volumn 48, Issue 5, 2015, Pages 575-579

  Kornfield, Rachel ^a   Alexander, G Caleb ^b,c,d   Qato, Dima M ^e,f   Kim, Yoonsang ^g   Hirsch, Jan D ^h,i   Emery, Sherry L ^g  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Outcomes and Policy ^*  (United States)

^f Center for Pharmacoepidemiology and Pharmacoeconomic Research   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ALLERGY; ARTHRITIS; ARTICLE; ASTHMA; DEPRESSION; DRUG INDICATION; DRUG MARKETING; ERECTILE DYSFUNCTION; HOUSEHOLD; HYPERCHOLESTEROLEMIA; MARKET; PRESCRIPTION; SLEEP DISORDER; SMOKING CESSATION; TELEVISION; TREND STUDY; UNITED STATES; CHRONIC DISEASE; DIRECT-TO-CONSUMER ADVERTIZING; HUMAN;

CHRONIC DISEASE; DIRECT-TO-CONSUMER ADVERTISING; HUMANS; PRESCRIPTION DRUGS; TELEVISION; UNITED STATES;

EID: 84928235471     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2014.12.001     Document Type: Article

References (34)

1. D. Arnold, and J.L. Oakley The politics and strategy of industry self-regulation: the pharmaceutical industry's principles for ethical direct-to-consumer advertising as a deceptive blocking strategy J Health Polit Policy Law 38 3 2013 1 40 10.1215/03616878-2079496
2. R. Kornfield, J. Donohue, E.R. Berndt, and G.C. Alexander Promotion of prescription drugs to consumers and providers, 2001-2010 PLoS One 8 3 2013 e55504 10.1371/journal.pone.0055504
3. F. Brounéus, G. Macleod, K. Maclennan, L. Parkin, and C. Paul Drug safety awareness in New Zealand: public knowledge and preferred sources for information J Prim Health Care 4 4 2012 288 293
4. M. Delbaere, Smith, and C. Malcolm Health care knowledge and consumer learning: the case of direct-to-consumer drug advertising Health Mark Q 23 3 2006 9 29 10.1080/07359680802086059
5. M.F. Hollon Direct-to-consumer advertising: a haphazard approach to health promotion JAMA 293 16 2005 2030 2033 10.1001/jama.293.16.2030
6. D.L. Frosch, D. Grande, D.M. Tarn, and R.L. Kravitz A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising Am J Public Health 100 1 2010 24 32 10.2105/AJPH.2008.153767
7. Z.F. Gellad, and K.W. Lyles Direct-to-consumer advertising of pharmaceuticals Am J Med 120 6 2007 475 480 10.1016/j.amjmed.2006.09.030
8. S.D. Myers, M.B. Royne, and G.D. Deitz Direct-to-consumer advertising: exposure, behavior, and policy implications J Public Policy Mark 30 1 2011 110 118 10.1509/jppm.30.1.110
9. J.M. Donohue, E.R. Berndt, M. Rosenthal, A.M. Epstein, and R.G. Frank Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression Med Care 42 12 2004 1176 1185 10.1097/00005650-200412000-00004
10. G. Kalyanaram, and J.J. Phelan Effects of direct-to-consumer advertising of prescription drugs on prices J Bus Econ Stud 17 2 2011 67 76
11. J.E. Calfee, C. Winston, and R. Stempski Direct-to-Consumer advertising and the demand for cholesterol-reducing drugs J Law Ecomomics 45 2002 673 690 10.1086/374704
12. M.L. Capella, C.R. Taylor, R.C. Campbell, and L.S. Longwell Do pharmaceutical marketing activities raise prices? Evidence from five major therapeutic classes J Public Policy Mark 28 2 2009 146 161 10.1509/jppm.28.2.146
13. R.A. Hansen, and M. Droege Methodological challenges surrounding direct-to-consumer advertising research - The measurement conundrum Res Soc Adm Pharm 1 2 2005 331 347 10.1016/j.sapharm.2005.03.005
14. E.D. Brownfield, J.M. Bernhardt, J.L. Phan, M.V. Williams, R.M. Parker, and D.W. Light Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement J Health Commun 9 6 2004 491 497 10.1080/10810730490523115
15. H. Brody, and D.W. Light The inverse benefit law: how drug marketing undermines patient safety and public health Am J Public Health 101 3 2011 399 404 10.2105/AJPH.2010.199844
16. Nielsen 2012-2013 DMA ranks. 2012. www.tvb.org/measurement/131627.
17. M.B. Rosenthal, E.R. Berndt, J.M. Donohue, R.G. Frank, and A.M. Epstein Promotion of prescription drugs to consumers N Engl J Med 346 7 2002 498 505 10.1056/NEJMsa012075
18. R.M. Green Direct-to-consumer advertising and pharmaceutical ethics: the case of Vioxx Hofstra Law Rev 35 2006 749 759
19. Sheila Campbell. CBO economic and budget issue brief: promotional spending for prescription drugs. 2009. www.cbo.gov/sites/default/files/cbofiles/ftpdocs/105xx/doc10522/12-02-drugpromo-brief.pdf.
20. M. Aitken, E.R. Berndt, and D.M. Cutler Prescription drug spending trends in the United States: looking beyond the turning point Health Aff (Millwood) 28 1 2009 w151 w160 10.1377/hlthaff.28.1.w151
21. B.A. Liang, and T.K. Mackey Prevalence and global health implications of social media in direct-to-consumer drug advertising J Med Internet Res 13 3 2011 e64 10.2196/jmir.1775
22. B.A. Liang, and T. Mackey Direct-to-consumer advertising with interactive internet media: global regulation and public health issues JAMA 305 8 2011 824 825 10.1001/jama.2011.203
23. Saul S. F.D.A. issues warning on sleeping pills. The New York Times. March 15, 2007. www.nytimes.com/2007/03/15/business/14sleep.web.html.
24. D.C. Ling, E.R. Berndt, and M.K. Kyle Deregulating direct to consumer marketing of prescription drugs: effects on prescription and over the counter product sales J Law Econ 45 suppl 2 2002 691 723 10.1086/368004
25. H.A. Huskamp, J.M. Donohue, C. Koss, E.R. Berndt, and R.G. Frank Generic entry, reformulations, and promotion of SSRIs Pharmacoeconomics 26 7 2008 603 616 10.2165/00019053-200826070-00007
26. R. Moynihan, I. Heath, and D. Henry Selling sickness: the pharmaceutical industry and disease mongering BMJ 324 7342 2002 886 891 10.1136/bmj.324.7342.886
27. K.M. Kamal, S.P. Desselle, P. Rane, R. Parekh, and C. Zacker Content analysis of FDA warning letters to manufacturers of pharmaceuticals and therapeutic biologicals for promotional violations Drug Inf J 43 4 2009 385 393
28. B. Mintzes Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med 3 4 2006 e198 10.1371/journal.pmed.0030198
29. K.A. Kaphingst, W. DeJong, R.E. Rudd, and L.H. Daltroy A content analysis of direct-to-consumer television prescription drug advertisements J Health Commun 9 6 2004 515 528 10.1080/10810730490882586
30. K.M. Fain, and G.C. Alexander Mind the gap: understanding the effects of pharmaceutical direct-to-consumer advertising Med Care 52 4 2014 291 293 10.1097/MLR.0000000000000126
31. L. Chiou, and C. Tucker How Does Pharmaceutical Advertising Affect Consumer Search? 2010 Social Science Research Network Rochester, NY (Report No.: ID 1542934). http://papers.ssrn.com/abstract=1542934
32. T.M. Hale, A.S. Pathipati, S. Zan, and K. Jethwani Representation of health conditions on Facebook: content analysis and evaluation of user engagement J Med Internet Res 16 8 2014 e182 10.2196/jmir.3275
33. V. Lachhwani, and S. Ghose Online information seeking for prescription drugs Int J Bus Syst Res 6 1 2012 1 17 10.1504/IJBSR.2012.044020
34. K. Logan And now a word from our sponsor: do consumers perceive advertising on traditional television and online streaming video differently? J Mark Commun 19 4 2012 258 276 10.1080/13527266.2011.631568